Δ9-Tetrahydrocannabinol, cannabidiol (CBD), and cannabinol are the three major cannabinoids contained in marijuana, which are devoid of nitrogen atoms in their structures. In this study, we investigated the inhibitory effects of the major phytocannabinoids on the catalytic activity of human CYP2D6. These major cannabinoids inhibited the 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) and dextromethorphan O-demethylase activities of recombinant CYP2D6 and pooled human liver microsomes in a concentration-dependent manner (IC50 = 4.01–24.9 μM), indicating the strongest inhibitory potency of CBD. However, these cannabinoids showed no or weak metabolism-dependent inhibition. CBD competitively inhibited the CYP2D6 activities with the apparent Ki values of 1.16 to 2.69 μM. To clarify the structural requirement for CBD-mediated CYP2D6 inhibition, effects of CBD-related compounds on the AMMC O-demethylase activity of recombinant CYP2D6 were examined. Olivetol (IC50 = 7.21 μM) inhibited CYP2D6 activity as potently as CBD did (IC50 = 6.52 μM), whereas d-limonene did not show any inhibitory effect. Pentylbenzene failed to inhibit CYP2D6 activity. Furthermore, neither monomethyl nor dimethyl ethers of CBD inhibited the activity. Cannabidivarin having a propyl side chain inhibited CYP2D6 activity; its inhibitory effect (IC50 = 10.2 μM) was less potent than that of CBD. On the other hand, orcinol and resorcinol showed lack of inhibition. The inhibitory effect of CBD on CYP2D6 activity was more potent than those of 16 compounds without nitrogen atoms tested, such as progesterone. These results indicated that CBD caused potent direct CYP2D6 inhibition, in which two phenolic hydroxyl groups and the pentyl side chain of CBD may play important roles.
Seventy eight N3-substituted derivatives of uridine (1), thymidine (2), 2′-deoxyuridine (3), 6-azauridine (4), 2′,3′-O-isopropylideneuridine (5), and arabinofuranosyluracil (6) were synthesized and their antinociceptive effects were evaluated. N3-(2′,4′-Dimethoxyphenacyl)uridine (1l), N3-(2′,4′-dimethoxyphenacyl)2′-deoxyuridine (3l), and N3-(2′,5′-dimethoxyphenacyl)arabinofuranosyluracil (6m) possessed 93, 86, and 82% of the antinociceptive effects tested by hot plate, respectively. The antinociceptive effects of three derivatives were 5.8, 5.4, and 5.1-folds of the effect of N3-phenacyluridine (1h) (16%), respectively. The structure–activity relationship of N3-substituted pyrimidine nucleosides was also discussed.
We previously proposed on the underwater cable-driven parallel robot (UCDPR), a system comprising multiple surface robots, and designed a modeling and trajectory tracking control method for it. However, the conventional trajectory tracking control of the UCDPR using the kinematic controller faced several issues. These included challenges in control gain tuning due to model uncertainty and a decline in trajectory tracking performance caused by changes in system characteristics due to environmental factors like current velocity. In response, this study focuses on the development of an adaptive kinematic controller. The aim is to mitigate the effects of uncertainties and other factors while ensuring effective trajectory tracking. This is achieved by incorporating an adaptive modification term into the conventional kinematic controller, which can be tuned adaptively in real-time. To validate the effectiveness of the adaptive kinematic controller, we conducted numerical simulations using a planar 2-DOF UCDPR.